Literature DB >> 16358446

Swedish guidelines for the management of community-acquired pneumonia in immunocompetent adults.

Jonas Hedlund1, Kristoffer Strålin, Ake Ortqvist, Hans Holmberg.   

Abstract

This document presents the evidence-based guidelines of the Swedish Society of Infectious Diseases for the management of adult immunocompetent patients with community-acquired pneumonia (CAP), who are assessed at hospital. The prognostic score 'CURB-65' is recommended for all CAP patients in the emergency room. The score provides an assessment tool for the decision regarding outpatient treatment or level of hospital supervision, the choice of microbiological investigations, and empirical antibiotic treatment. In patients with non-severe CAP (CURB-65 score 0-2) we recommend initial narrow-spectrum antibiotic treatment, orally or intravenously, primarily directed at Streptococcus pneumoniae. In those with CURB-65 score 3, penicillin G or a cephalosporin intravenously is recommended. For CURB-65 score 0-3 atypical pathogens should be covered only when they are suspected on clinical or epidemiological grounds. In patients with CURB-65 score 4-5 intravenous combination therapy with either cephalosporin/macrolide or penicillin G/fluoroquinolone is recommended. Efforts should be made to identify the CAP aetiology in order to support the ongoing antibiotic treatment or to suggest treatment alterations. Recommended measures for prevention of CAP include influenza -- and pneumococcal -- vaccination to risk groups and efforts for smoking cessation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16358446     DOI: 10.1080/00365540500264050

Source DB:  PubMed          Journal:  Scand J Infect Dis        ISSN: 0036-5548


  6 in total

Review 1.  Empiric antibiotic coverage of atypical pathogens for community-acquired pneumonia in hospitalized adults.

Authors:  Noa Eliakim-Raz; Eyal Robenshtok; Daphna Shefet; Anat Gafter-Gvili; Liat Vidal; Mical Paul; Leonard Leibovici
Journal:  Cochrane Database Syst Rev       Date:  2012-09-12

2.  Utility of two biomarkers for directing care among patients with non-severe community-acquired pneumonia.

Authors:  P P España; A Capelastegui; A Bilbao; R Diez; F Izquierdo; M J Lopez de Goicoetxea; J Gamazo; F Medel; J Salgado; I Gorostiaga; J M Quintana
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-08-05       Impact factor: 3.267

Review 3.  Antibiotics for community-acquired pneumonia in adult outpatients.

Authors:  Smita Pakhale; Sunita Mulpuru; Theo J M Verheij; Michael M Kochen; Gernot G U Rohde; Lise M Bjerre
Journal:  Cochrane Database Syst Rev       Date:  2014-10-09

4.  Posterior mediastinal extramedullary hematopoiesis secondary to hypoxia.

Authors:  A Solazzo; V D'Auria; L G Moccia; A Vatrella; M Bocchino; G Rea
Journal:  Transl Med UniSa       Date:  2016-05-16

5.  Application of vibration response imaging technology in patients with community-acquired pneumonia before and after the treatment.

Authors:  Hongying Jiang; Jichao Chen; Jinying Cao; Lan Mu; Zhenyu Hu; Jian He
Journal:  Exp Ther Med       Date:  2017-05-03       Impact factor: 2.447

6.  Severity of influenza A 2009 (H1N1) pneumonia is underestimated by routine prediction rules. Results from a prospective, population-based study.

Authors:  Agnar Bjarnason; Gudlaug Thorleifsdottir; Arthur Löve; Janus F Gudnason; Hilmir Asgeirsson; Kristinn L Hallgrimsson; Berglind S Kristjansdottir; Gunnsteinn Haraldsson; Olafur Baldursson; Karl G Kristinsson; Magnus Gottfredsson
Journal:  PLoS One       Date:  2012-10-11       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.